A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
For more information about the trial above please contact the study team:
Principal Investigator, Irl Greenwell, at email@example.com, or please call +1 843-792-4759.
Study Coordinator, Sarah Britton, at firstname.lastname@example.org, or please call +1 843-792-8856.
Trial opened at the following institutions: Medical University of South Carolina